Healthcare Integrity & Anti-Fraud Enforcement
Condition(s) studied
Investigational drug(s) / intervention(s)
Validator-Governed Reform & Regulatory Escalation Protocol: This intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based.
Coalition-Grade Validator Dashboard Module (CVDM-1): The Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains.
Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1): The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains.
Study summary
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Eligibility
Primary outcome measure(s)
- Change in Fraudulent Billing and Kickback Incidents Across Enrolled Facilities — Baseline to 12 Months Post-Validator Onboarding
Description: This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols. Facilities are assessed using the Unified Impact Index derived from: Historical billing anomalies Validator audit results Whistleblower declarations SHA-256 hash-anchored incident reports Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards. Time Frame: Baseline to 12 Months Post-Validator Onboarding.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016 | New York | New York |
More Truway Health, Inc. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07217730 on ClinicalTrials.gov ↗ ← All trials in the USA